PF-6142

PF-6142 is a novel, non-catecholamine small molecule agonist of the dopamine D1 and D5 receptors (D1R/D5R). Developed by Pfizer, it was designed to address the poor pharmacokinetic profiles and lack of oral bioavailability associated with traditional catechol-based dopamine agonists. PF-6142 demonstrates functionally biased signaling and has shown pro-cognitive effects in preclinical models, including reversing ketamine-induced deficits in non-human primates and improving working memory in rodents. It is being investigated for the treatment of cognitive impairment associated with schizophrenia (CIAS) and other neurological disorders like Parkinson's disease, as it enhances prefrontal cortex acetylcholine release and desynchronizes EEG patterns without diminishing the efficacy of standard antipsychotics.